左卡尼汀治疗慢性肾衰竭合并贫血及高脂血症的疗效

The effect of levocarnitine in the treatment of anemia and hyperlipidemia accompanied with chromic renal failure

目的观察左卡尼汀治疗慢性肾衰竭血液透析患者的贫血及高脂血症的疗效。方法将42例慢性肾衰竭血液透析患者随机分成治疗组和对照组,两组患者均于血液透析后皮下注射促红细胞生成素,剂量为每周80-120 U/kg,待血红蛋白（Hb）〉11 g/dl或血细胞比容（Hct）上升至33%后减量。同时治疗组每次血液透析后静脉注射左卡尼汀1.0g,疗程12周。结果治疗组的Hb、Hct水平显著高于对照组（P〈0.05）。治疗组于治疗后第12周促红细胞生成素用量较治疗前减少。同时治疗组的胆固醇（TC）、甘油三酯（TG）水平较治疗前下降。结论左卡尼汀能提高促红细胞生成素治疗肾性贫血的疗效,同时改善慢性肾衰竭患者脂代谢紊乱。

Objective To observe the curative effect of the therapy with levocarnitine in CRF patients with anemia and hyperlipidemia undergoing hemodialysis. Methods Forty-two CRF patients undergoing hemodialysis were randomly divided into the rapeautic group and control group.The normal therapies of two groups were the same,all patients were received subcutaneous inje ction with 80-120 U/kg erythropoietin once a week.The dosage of erythropoietin wasn＇t reduced untill the HGB〉11g/dl or the hematocrit increased to 33%,and the therapeacitic group was given levocarnitine 1.0 g every time by intravenous injection after hemodialysis.The treatment course lasted 12 weeks.Results Compared with the control group,the levels of hemoglobin and hematocrit were significantly increased in the therapeacitic group（P〈0.05）.After 12 weeks treatment,the dosage of erythropoietin in therapeautic group was reduced significantly,while no remarkable change in control group.At the same time,the serum TG and TC levels in therapeacitic group were found much lower than that before treatment.Conclusions Levocarnitine may enhance the curative effect of erythropoietin,and correct the dyslipidemia in CRF patients.